---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001872"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:49:34.345008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical Q3 net loss $6.0M; $5M equity financing; GLP-1 implant study approved in Australia

## Summary
- Net loss $6.0M for Q3 2024 vs $6.8M YoY; cash $21.0M as of Sept 30, 2024.
- Regulatory approval in Australia for LIBERATE-1 Phase 1 trial of GLP-1 (exenatide) implant in obese/overweight patients.
- Private sale of 3.97M shares at $1.26/share to a director for $5.0M gross proceeds, extending runway into late 2025.
- Preclinical data: 82% sham-implant adjusted liver fat reduction and 20% weight loss comparable to semaglutide.
- R&D expense $4.2M (-5% YoY); G&A $2.1M (-22% YoY); operating expenses decreased $0.8M.

## SEC filing metadata
- accession: 0001753926-24-001872
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001872/0001753926-24-001872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001872/vani-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001872
- JSON: https://secwatch.observer/filing/0001753926-24-001872.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.